# Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1

> **NCT00396149** · PHASE1 · COMPLETED · sponsor: **Stallergenes Greer** · enrollment: 57 (actual)

## Conditions studied

- Birch Pollen-Related Rhinoconjunctivitis
- Rhinitis, Allergic, Seasonal

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** rBet v 1

## Key facts

- **NCT ID:** NCT00396149
- **Lead sponsor:** Stallergenes Greer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-03
- **Final completion:** 2007-06
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2013-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396149, "Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00396149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*